Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Faron Pharmaceuticals Company Event

By Inderes
Faron Pharmaceuticals

Regulatory Press Release (6/4/2024): Faron commences a share offering 

More information regarding the public offering: https://www.faron.com/landing-page


Faron Pharmaceuticals is a clinical-stage biopharmaceutical company based in Finland and the United States, with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the Clever-1 target on myeloid cells and macrophages.

Clever-1 is an immunosuppressive receptor that promotes tumor growth and metastases when expressed on macrophages. Bexmarilimab primes the tumor microenvironment for optimal antitumor immune responses, in both hematological malignancies and solid tumors.

Stay up to date
Investor events

Recent videos

HCA Morgenbørs 19/12 - Små fald i den europæiske åbning og fokus på flere danske aktier
19.12.2025, 09.25 Aquaporin
Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025, 11.00 Talenom
HCA Morgenbørs 18/12 - Vi ser ind i en flad europæiske åbning trods markante US fald, vi undgår igen tech-nedturen
18.12.2025, 09.55 ISS
Flügger - Q2 2025/26 Analytiker video
18.12.2025, 09.46 Flügger Group
Investing in the life science sector
18.12.2025, 07.47
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.